Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Catenacci, DVT; Park, H; Uronis, HE; Kang, Y-K; Lacy, J; Enzinger, PC; Park, SH; Lee, KW; Ng, MCH; Gold, PJ; Yen, J; Franovic, A; Kelly, RJ; Wynter-Horton, A; Li, D; Muth, J; Baughman, JE; Hong, S; Davidson-Moncada, JK; Bang, Y-J

Published Date

  • May 20, 2018

Published In

Volume / Issue

  • 36 / 15_suppl

Start / End Page

  • 4030 - 4030

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2018.36.15_suppl.4030